Literature DB >> 24523360

Integrating contrast-enhanced sonography in the follow-up algorithm of hepatocellular carcinoma treated with radiofrequency ablation: single cancer center experience.

Orlando Catalano1, Francesco Izzo2, Paolo Vallone3, Fabio Sandomenico3, Vittorio Albino2, Antonio Nunziata4, Roberta Fusco3, Antonella Petrillo3.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) patients treated with percutaneous ablation require close follow-up for early detecting and treating tumor recurrence.
PURPOSE: To illustrate our single-center prospective experience on using contrast-enhanced ultrasound (CEUS) as a follow-up tool alternated with computed tomography (CT).
MATERIAL AND METHODS: In a 7-year period 588 patients with one to three HCCs were treated with radiofrequency ablation (alone or combined with ethanol injection). Patients with completely ablated tumors at 1-month CT scan were followed up serially, using alternated CEUS (one microbubbles injection per lobe) and CT every 3 months for 2 years. In few cases magnetic resonance imaging (MRI) was employed instead of or in addition to CT. The following patterns of recurrence were considered: A, enhancing tissue within the lesion; B, enhancing tissue adherent to the lesion; C, enhancing tissue within the same liver segment of the treated nodule; and D, enhancing tissue within a different segment. Patients with positive CEUS underwent confirmatory CT/MRI (standard reference).
RESULTS: Median follow-up was 19 months. There were 221 recurrences. Three pattern A recurrences (2 detected by CEUS and 1 by CT), 86 pattern B recurrences (44 detected by CEUS and 42 by CT), 70 pattern C recurrences (32 detected by CEUS and 38 by CT), and 62 pattern D recurrences (23 detected by CEUS and 39 by CT). CT detected additional nodules in 16/101 patients with positive CEUS.
CONCLUSION: CEUS follow-up of HCC patients after ablation is feasible. Since 72% recurrences develop in the same segment of the necrotic nodule, CEUS proves to be effective despite the minor visualization of the entire liver during the arterial phase when compared to CT and MRI. Including CEUS in patient follow-up may reduce the number of CT and MRI examinations. © The Foundation Acta Radiologica 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.

Entities:  

Keywords:  Hepatocellular carcinoma; contrast-enhanced sonography; follow-up strategy; radiofrequency ablation; tumor recurrence

Mesh:

Substances:

Year:  2014        PMID: 24523360     DOI: 10.1177/0284185114521108

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  9 in total

1.  Multimodality imaging to assess immediate response following irreversible electroporation in patients with malignant hepatic tumors.

Authors:  Katsutoshi Sugimoto; Fuminori Moriyasu; Kazuhiro Saito; Yoshiyuki Kobayashi; Takao Itoi
Journal:  J Med Ultrason (2001)       Date:  2016-12-08       Impact factor: 1.314

Review 2.  Loco-regional treatment of hepatocellular carcinoma: Role of contrast-enhanced ultrasonography.

Authors:  Agostino Inzerillo; Maria Franca Meloni; Adele Taibbi; Tommaso Vincenzo Bartolotta
Journal:  World J Hepatol       Date:  2022-04-07

3.  Irreversible electroporation of hepatocellular carcinoma: preliminary report on the diagnostic accuracy of magnetic resonance, computer tomography, and contrast-enhanced ultrasound in evaluation of the ablated area.

Authors:  Vincenza Granata; Elisabetta de Lutio di Castelguidone; Roberta Fusco; Orlando Catalano; Mauro Piccirillo; Raffaele Palaia; Francesco Izzo; Adolfo D'Errico Gallipoli; Antonella Petrillo
Journal:  Radiol Med       Date:  2015-09-07       Impact factor: 3.469

Review 4.  Contrast-enhanced ultrasonography of the liver using SonoVue.

Authors:  Giovanna Ferraioli; Maria Franca Meloni
Journal:  Ultrasonography       Date:  2017-07-12

5.  Effect of NET-1 siRNA conjugated sub-micron bubble complex combined with low-frequency ultrasound exposure in gene transfection.

Authors:  Bolin Wu; Xitian Liang; Hui Jing; Xue Han; Yixin Sun; Cunli Guo; Ying Liu; Wen Cheng
Journal:  Oncotarget       Date:  2017-12-23

6.  A new proposal for secondary surveillance following potentially curative therapy of HCC: alternating MRI and CEUS.

Authors:  Sanjay Bansal; Fangshi Lu; Levi Frehlich; Jason K Wong; Kelly W Burak; Stephanie R Wilson
Journal:  Abdom Radiol (NY)       Date:  2021-11-20

Review 7.  A Systematic Review about Imaging and Histopathological Findings for Detecting and Evaluating Electroporation Based Treatments Response.

Authors:  Vincenza Granata; Roberta Fusco; Simona Salati; Antonella Petrillo; Elio Di Bernardo; Roberta Grassi; Raffaele Palaia; Ginevra Danti; Michelearcangelo La Porta; Matteo Cadossi; Gorana Gašljević; Gregor Sersa; Francesco Izzo
Journal:  Int J Environ Res Public Health       Date:  2021-05-24       Impact factor: 3.390

Review 8.  Diagnostic evaluation and ablation treatments assessment in hepatocellular carcinoma.

Authors:  Vincenza Granata; Roberta Grassi; Roberta Fusco; Andrea Belli; Carmen Cutolo; Silvia Pradella; Giulia Grazzini; Michelearcangelo La Porta; Maria Chiara Brunese; Federica De Muzio; Alessandro Ottaiano; Antonio Avallone; Francesco Izzo; Antonella Petrillo
Journal:  Infect Agent Cancer       Date:  2021-07-19       Impact factor: 2.965

Review 9.  Radio-frequency ablation-based studies on VX2rabbit models for HCC treatment.

Authors:  Sabrina Bimonte; Maddalena Leongito; Mauro Piccirillo; Cristina de Angelis; Claudia Pivonello; Vincenza Granata; Francesco Izzo
Journal:  Infect Agent Cancer       Date:  2016-08-12       Impact factor: 2.965

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.